Purpose: The aerial parts of Dracocephalum moldavica L. (DM) have been widely used as traditional herbal medicine for cardiovascular diseases and skin problems in Central Asia and Europe. This study evaluated the photoprotective effects of three different DM seed (DMS) extracts against ultraviolet B (UVB)-induced photoaging in human dermal fibroblasts (HDFs) and human keratinocytes (HaCaT cells). Methods: DMS extracts were prepared using supercritical fluid (SC-oil), ethanol (EE), and aqueous (AE) methods. Their ability to regulate the extracellular matrix (ECM) components, including procollagen type I (PC1), matrix metalloproteinase-1 (MMP-1), and elastase-1, which are key biomarkers of photoaging, was evaluated. Results: All extracts restored procollagen synthesis, reduced MMP-1 and elastase-1 production and activity, and upregulated PC1 mRNA expression while downregulating the MMP-1 and elastase-1 mRNA levels in UVB-irradiated cells. SC-oil (0.0001%) and AE (0.125 mg/mL) reversed the PC1 mRNA levels most effectively in HDFs and HaCaT cells, respectively.In addition, SC-oil had the strongest suppressive effect on MMP-1 secretion in HDFs, while EE and AE were more effective in HaCaT cells. The elastase-1 activity and mRNA levels in both cell types were comparable to those treated with L-ascorbic acid, a positive control. Conclusion These findings suggest that DMS extracts, rich in bioactive compounds such as polyphenols, phytosterols, and omega-3 polyunsaturated fatty acids, have significant potential as natural anti-aging agents. By protecting collagen and elastin integrity and modulating ECM biomarkers, DMS extracts may effectively prevent UVB-induced photoaging and improve skin resiliency.

Purpose: The aerial parts of Dracocephalum moldavica L. (DM) have been widely used as traditional herbal medicine for cardiovascular diseases and skin problems in Central Asia and Europe. This study evaluated the photoprotective effects of three different DM seed (DMS) extracts against ultraviolet B (UVB)-induced photoaging in human dermal fibroblasts (HDFs) and human keratinocytes (HaCaT cells). Methods: DMS extracts were prepared using supercritical fluid (SC-oil), ethanol (EE), and aqueous (AE) methods. Their ability to regulate the extracellular matrix (ECM) components, including procollagen type I (PC1), matrix metalloproteinase-1 (MMP-1), and elastase-1, which are key biomarkers of photoaging, was evaluated. Results: All extracts restored procollagen synthesis, reduced MMP-1 and elastase-1 production and activity, and upregulated PC1 mRNA expression while downregulating the MMP-1 and elastase-1 mRNA levels in UVB-irradiated cells. SC-oil (0.0001%) and AE (0.125 mg/mL) reversed the PC1 mRNA levels most effectively in HDFs and HaCaT cells, respectively.In addition, SC-oil had the strongest suppressive effect on MMP-1 secretion in HDFs, while EE and AE were more effective in HaCaT cells. The elastase-1 activity and mRNA levels in both cell types were comparable to those treated with L-ascorbic acid, a positive control. Conclusion These findings suggest that DMS extracts, rich in bioactive compounds such as polyphenols, phytosterols, and omega-3 polyunsaturated fatty acids, have significant potential as natural anti-aging agents. By protecting collagen and elastin integrity and modulating ECM biomarkers, DMS extracts may effectively prevent UVB-induced photoaging and improve skin resiliency.

Purpose: The aerial parts of Dracocephalum moldavica L. (DM) have been widely used as traditional herbal medicine for cardiovascular diseases and skin problems in Central Asia and Europe. This study evaluated the photoprotective effects of three different DM seed (DMS) extracts against ultraviolet B (UVB)-induced photoaging in human dermal fibroblasts (HDFs) and human keratinocytes (HaCaT cells). Methods: DMS extracts were prepared using supercritical fluid (SC-oil), ethanol (EE), and aqueous (AE) methods. Their ability to regulate the extracellular matrix (ECM) components, including procollagen type I (PC1), matrix metalloproteinase-1 (MMP-1), and elastase-1, which are key biomarkers of photoaging, was evaluated. Results: All extracts restored procollagen synthesis, reduced MMP-1 and elastase-1 production and activity, and upregulated PC1 mRNA expression while downregulating the MMP-1 and elastase-1 mRNA levels in UVB-irradiated cells. SC-oil (0.0001%) and AE (0.125 mg/mL) reversed the PC1 mRNA levels most effectively in HDFs and HaCaT cells, respectively.In addition, SC-oil had the strongest suppressive effect on MMP-1 secretion in HDFs, while EE and AE were more effective in HaCaT cells. The elastase-1 activity and mRNA levels in both cell types were comparable to those treated with L-ascorbic acid, a positive control. Conclusion These findings suggest that DMS extracts, rich in bioactive compounds such as polyphenols, phytosterols, and omega-3 polyunsaturated fatty acids, have significant potential as natural anti-aging agents. By protecting collagen and elastin integrity and modulating ECM biomarkers, DMS extracts may effectively prevent UVB-induced photoaging and improve skin resiliency.

Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience.However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA providessome guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted tounderstand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions Study finds TKI-DDI not significantlylinked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.

Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience.However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA providessome guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted tounderstand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions Study finds TKI-DDI not significantlylinked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.

Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience.However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA providessome guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted tounderstand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions Study finds TKI-DDI not significantlylinked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.

Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience.However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA providessome guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted tounderstand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions Study finds TKI-DDI not significantlylinked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.

BACKGROUND/OBJECTIVES: This study analyzed the quality of lunches provided in senior leisure service (SLS) facilities and compared institutional foodservice (IF) and noninstitutional foodservice (non-IF). SUBJECTS/METHODS: Data of 390 adults aged 65 years or older who ate lunches in SLS facilities were analyzed using the information from the 2013–2017 Korea National Health and Nutrition Examination Survey. The participants were classified into IF (n = 129) and non-IF (n = 261) groups according to meal type provided. The intake of major food groups, energy and nutrients, and nutrient adequacy ratio (NAR) and mean adequacy ratio (MAR) were analyzed. The diversity of meals was evaluated by food group patterns, dietary diversity score (DDS) and dietary variety score (DVS). Energy intake was adjusted in model 1, while energy and sex were adjusted in model 2. All confounding variables were adjusted in model 3. RESULTS: The intake of seafoods (P < 0.001 in models 1, 2, and 3), seaweeds (P < 0.01 in models 1 and 2), and dairy products (P < 0.05 in models 1, 2, and 3) was significantly higher in the IF group. No significant difference existed in energy intake; however, the intake of all nutrients except carbohydrate and vitamin C was significantly higher in the IF group. NAR of all nutrients, excluding vitamin C, was higher in the IF group, and MAR was also higher in the IF group (P < 0.001 in models 1, 2, and 3). The IF group had significantly higher DDS and DVS than the non-IF group (P < 0.001). CONCLUSIONS The lunches provided in SLS facilities were better in terms of quantity and quality when provided through IF than through non-IF. More systematic foodservice programs should be implemented in SLS facilities, especially in facilities wherein users prepare their own meals.

BACKGROUND/OBJECTIVES: This study analyzed the quality of lunches provided in senior leisure service (SLS) facilities and compared institutional foodservice (IF) and noninstitutional foodservice (non-IF). SUBJECTS/METHODS: Data of 390 adults aged 65 years or older who ate lunches in SLS facilities were analyzed using the information from the 2013–2017 Korea National Health and Nutrition Examination Survey. The participants were classified into IF (n = 129) and non-IF (n = 261) groups according to meal type provided. The intake of major food groups, energy and nutrients, and nutrient adequacy ratio (NAR) and mean adequacy ratio (MAR) were analyzed. The diversity of meals was evaluated by food group patterns, dietary diversity score (DDS) and dietary variety score (DVS). Energy intake was adjusted in model 1, while energy and sex were adjusted in model 2. All confounding variables were adjusted in model 3. RESULTS: The intake of seafoods (P < 0.001 in models 1, 2, and 3), seaweeds (P < 0.01 in models 1 and 2), and dairy products (P < 0.05 in models 1, 2, and 3) was significantly higher in the IF group. No significant difference existed in energy intake; however, the intake of all nutrients except carbohydrate and vitamin C was significantly higher in the IF group. NAR of all nutrients, excluding vitamin C, was higher in the IF group, and MAR was also higher in the IF group (P < 0.001 in models 1, 2, and 3). The IF group had significantly higher DDS and DVS than the non-IF group (P < 0.001). CONCLUSIONS The lunches provided in SLS facilities were better in terms of quantity and quality when provided through IF than through non-IF. More systematic foodservice programs should be implemented in SLS facilities, especially in facilities wherein users prepare their own meals.

BACKGROUND/OBJECTIVES: Gastrodia elata Blume (GEB), a traditional herbal medicine, has been used to treat a wide range of neurological disorders (e.g., paralysis and stroke) and skin problems (e.g., atopic dermatitis and eczema) in oriental medicine. This study was designed to investigate whether GEB extract inhibits melanogenesis activity in murine B16F10 melanoma. MATERIALS/METHOD: Murine B16F10 cells were treated with 0-5 mg/mL of GEB extract or 400 µg/mL arbutin (a positive control) for 72 h after treatment with/without 200 nM alpha-melanocyte stimulating hormone (α-MSH) for 24 h. Melanin concentration, tyrosinase activity, mRNA levels, and protein expression of microphthalmia-associated transcription factor (MITF), tyrosinase, tyrosinase-related protein (Trp)1, and Trp2 were analyzed in α-MSH-untreated and α-MSH-treated B16F10 cells. RESULTS: Treatment with 200 nM α-MSH induced almost 2-fold melanin synthesis and tyrosinase activity along with increased mRNA levels and protein expression of MITF, tyrosinase, Trp1 and Trp2. Irrespective of α-MSH stimulation, GEB extract at doses of 0.5-5 mg/mL inhibited all these markers for skin whitening in a dose-dependent manner. While lower doses (0.5-1 mg/mL) of GEB extract generally had a tendency to decrease melanogenesis, tyrosinase activity, and mRNA levels and protein expression of MITF, tyrosinase, Trp1, and Trp2, higher doses (2-5 mg/mL) significantly inhibited all these markers in α-MSH-treated B16F10 cells in a dose-dependent manner. These inhibitory effects of the GEB extract at higher concentrations were similar to those of 400 µg/mL arbutin, a well-known depigmenting agent. CONCLUSIONS: These results suggest that GEB displays dose-dependent inhibition of melanin synthesis through the suppression of tyrosinase activity as well as molecular levels of MITF, tyrosinase, Trp1, and Trp2 in murine B16F10 melanoma. Therefore, GEB may be an effective and natural skin-whitening agent for application in the cosmetic industry.
Arbutin ; Dermatitis, Atopic ; Gastrodia* ; Herbal Medicine ; Medicine, East Asian Traditional ; Melanins ; Melanoma* ; Microphthalmia-Associated Transcription Factor ; Monophenol Monooxygenase ; Nervous System Diseases ; Paralysis ; RNA, Messenger ; Skin ; Skin Lightening Preparations